United Therapeutics Corporation UTHR

US Biotechnology

$580.71 ▼ -0.30% ($-1.75)

Open $580.52

Prev Close $582.46

Day Range $577.26 – $582.85

52W Range $444.04 – $614.23

Market Cap $25.68B

P/E (TTM) 19.45

Beta 0.47

EPS (TTM) $26.51

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	1999-06-17
Shares Out.	42,890,000
Website	unither.com/ ↗
Phone	13016089292
Employees	1,400
Revenue	$832.5M
Gross Profit	$733.4M
Net Income	$258.6M
Free Cash Flow	$867.2M
Total Assets	$7.03B
Total Liabilities	$758.1M
Equity	$6.28B

About United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

United Therapeutics Corporation is a publicly traded company under the ticker symbol UTHR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.